Antoine Yver MD MSc

Chairman of Development

Dr. Antoine Yver, MD, MSc, serves as Chairman of Development at Centessa Pharmaceuticals. Antoine brings more than 30 years of global experience in the pharmaceutical industry to Centessa and has led the approvals of 11 different drugs, including TAGRISSO®, LYNPARZA®, and ENHERTU®. He led the development of TAGRISSO® in 2 years and 7 months from first human dose to U.S. approval and its rapid deployment to all other major regions, which was the fastest ever for an anti-cancer drug. Antoine joined Centessa from Daiichi Sankyo Company, Ltd., where he served as Executive Vice President and Global Head, R&D Oncology, and Chair of the Cancer Enterprise. Antoine currently serves as an independent director on the Board of Sanofi (NASDAQ: SNY) and as an independent board member on the Board of Spotlight Therapeutics

Previously, Antoine was with AstraZeneca, PLC, most recently serving as Senior Vice President, Global Medicine Head, Oncology, and Global Medicines Development China Lead.

Earlier, Antoine held various clinical development roles at Schering-Plough/Merck, Johnson & Johnson, Aventis Pharmaceuticals, Inc., Rhône-Poulenc Rorer, Inc., Applied Immune Sciences, Inc., and Chugai-RP.

Antoine is a Pediatric Oncologist and holds an MD from Université Paris-Saclay.

Scroll to Top
pipeline chart header registrational white

SerpinPC is a subcutaneously administered novel inhibitor of APC being developed as a potential treatment for hemophilia, regardless of severity or inhibitor status, and may also prevent bleeding associated with other bleeding disorders. Centessa is advancing the registrational program for SerpinPC in hemophilia B, which includes a set of clinical studies with multiple components. PRESent-5, initiated in late 2022, is an observational feeder study to collect prospective observational data for minimum defined periods before switching to dosing subjects in the interventional studies. The interventional studies include PRESent-2 (moderately severe to severe hemophilia B without inhibitors, and severe hemophilia A with and without inhibitors) and PRESent-3 (hemophilia B with inhibitors). Additional information on the trials can be accessed at  (NCT05605678NCT05789524NCT05789537). SerpinPC is an investigational agent that has not been approved by the FDA or any other regulatory authority.

Reason to Believe in Target
Human Genetics Support

~20,000 persons with hemophilia in the United States
450,000 estimated global prevalence

Hemophilia B